Klausner Adam P, Streng Tomi, Na Yong-Gil, Raju Jerry, Batts Timothy W, Tuttle Jeremy B, Andersson Karl-Erik, Steers William D
Department of Urology, University of Virginia Health System, Charlottesville, 22908-0422, USA.
Auton Neurosci. 2005 Dec 30;123(1-2):26-35. doi: 10.1016/j.autneu.2005.08.003. Epub 2005 Oct 26.
The purpose of this investigation was to evaluate the role of corticotropin releasing factor (CRF) on micturition. CRF is involved in the endocrine and central nervous system responses to stress and is also expressed in sites responsible for the control of micturition. In this investigation, cystometric experiments were performed in awake and unrestrained Wistar rats and on Spontaneous Hypertensive Rats, which are used as a rodent model of detrusor overactivity and anxiety. In vitro effects of CRF were evaluated using strips of detrusor muscle in an organ bath preparation. CRF (6.0 microg) administered via intrathecal and intraperitoneal routes, but not intracerebroventricularly, lowered the micturition threshold. CRF reduced the intercontraction interval by 28% and 26% after intrathecal or intraperitoneal administration, respectively, and reduced micturition volume by 34.7% and 30.2%, respectively. In Wistar-Kyoto rats, 6.0 microg intrathecal CRF significantly reduced intercontraction interval (423 +/- 79 vs. 669 +/- 59 s) and micturition volume (0.30 +/- 0.04 vs. 0.69 +/- 0.07 ml) compared to controls that received saline vehicle. These effects were blocked by pretreatment with 6.0 mug intrathecal astressin, a potent CRF antagonist, demonstrating that the effects are CRF receptor mediated. In Spontaneous Hypertensive Rats, 6.0 mug intrathecal CRF was found to have minimal stimulatory effects on the bladder, whereas astressin reduced baseline detrusor overactivity. CRF had no direct contractile effects on detrusor muscle strips. These results demonstrate that in the absence of detrusor overactivity, CRF stimulates micturition when administered via the intrathecal or intraperitoneal routes. Further studies are needed to explore the possibility whether CRF antagonists are effective for detrusor overactivity and the overactive bladder syndrome.
本研究的目的是评估促肾上腺皮质激素释放因子(CRF)在排尿中的作用。CRF参与应激反应的内分泌和中枢神经系统反应,并且在负责排尿控制的部位也有表达。在本研究中,对清醒且不受束缚的Wistar大鼠和自发性高血压大鼠进行了膀胱测压实验,自发性高血压大鼠用作逼尿肌过度活动和焦虑的啮齿动物模型。使用器官浴制备中的逼尿肌条评估CRF的体外作用。通过鞘内和腹腔内途径而非脑室内给予CRF(6.0微克)可降低排尿阈值。鞘内或腹腔内给予CRF后,收缩间期分别缩短28%和26%,排尿量分别减少34.7%和30.2%。在Wistar-Kyoto大鼠中,与接受生理盐水载体的对照组相比,鞘内给予6.0微克CRF可显著缩短收缩间期(423±79对669±59秒)和排尿量(0.30±0.04对0.69±0.07毫升)。用6.0微克鞘内阿施他辛(一种有效的CRF拮抗剂)预处理可阻断这些作用,表明这些作用是由CRF受体介导的。在自发性高血压大鼠中,发现鞘内给予6.0微克CRF对膀胱的刺激作用极小,而阿施他辛可降低基线逼尿肌过度活动。CRF对逼尿肌条无直接收缩作用。这些结果表明,在没有逼尿肌过度活动的情况下,通过鞘内或腹腔内途径给予CRF可刺激排尿。需要进一步研究以探索CRF拮抗剂对逼尿肌过度活动和膀胱过度活动综合征是否有效的可能性。